Madrid, Spain – The 2026 European Society for Medical Oncology (ESMO) Congress, held in the vibrant heart of Madrid, has concluded, leaving an indelible mark on the global oncology landscape. This year’s gathering was characterized by an unprecedented convergence of scientific innovation, with potentially paradigm-shifting readouts across several solid tumor indications. However, it was the relentless pursuit of novel solutions in lung cancer that truly captivated attendees, spotlighting a critical area of unmet medical need and igniting fresh hope for millions worldwide.
n
Despite significant advancements in recent years, various forms of lung cancer continue to pose formidable challenges, with many patients, particularly those with specific genotypes or advanced disease stages, facing grim prognoses and limited therapeutic options. This urgent demand for novel drugs and combination regimens underscores the profound importance of the data presented at ESMO 2026, which promises to redefine treatment standards and markedly improve patient outcomes.
n
Amgen and AstraZeneca Forge New Path in Extensive-Stage Small-Cell Lung Cancer
n
One of the most anticipated revelations came from Amgen, in collaboration with AstraZeneca, presenting groundbreaking data for their bispecific T-cell engager (BiTE), Imdelltra (tarlatamab). During a highly attended Presidential Symposium, the Californian pharmaceutical giant unveiled positive results from the DeLLphi-305 trial (NCT06211036), a pivotal study evaluating a novel combination of Imdelltra and AstraZeneca’s immunotherapy powerhouse, Imfinzi (durvalumab), against Imfinzi monotherapy in the frontline maintenance setting for patients with extensive-stage small-cell lung cancer (ES-SCLC).
n
Small-cell lung cancer, particularly its extensive-stage variant, remains one of the most aggressive and recalcitrant forms of cancer, historically associated with notoriously poor outcomes. The five-year survival rate for ES-SCLC patients is tragically low, typically ranging between a mere 2.8% and 7%. Existing treatments have offered incremental gains, but a substantial leap forward has long been desperately sought.
n
Chronology of a Breakthrough: DeLLphi-305’s Unprecedented Efficacy
n
The DeLLphi-305 trial was designed to address this critical void, pitting the investigational Imfinzi-Imdelltra combination against Imfinzi alone. The results presented at ESMO 2026 were nothing short of remarkable. At a median follow-up of 15.9 months, the combination therapy demonstrated an astonishing 58% reduction in the risk of death compared to Imfinzi monotherapy. This translated into a median overall survival (OS) of 21.1 months for patients receiving the combination, an impressive 8.4-month improvement over the 12.7 months achieved with Imfinzi alone.
n
Beyond extending survival, the Imfinzi-Imdelltra duo also significantly delayed disease progression. The risk of disease progression or death was slashed by 66% compared to Imfinzi monotherapy, with patients on the combination arm achieving a median progression-free survival (PFS) of 7.4 months, a substantial gain over the 1.9 months observed in the control arm. Crucially, these profound treatment benefits were consistent across all prespecified subgroups, including those patients whose cancer had metastasized to challenging sites such such as the brain or liver – a particularly significant finding given the aggressive nature of ES-SCLC.
n
Official Responses and Implications for a Critical Patient Population
n
The clinical community’s response was overwhelmingly positive. William Blair analysts lauded the findings as "impressive," underscoring the potential for a transformative impact. Leora Horn, Senior Vice President of Late Development Oncology and Oncology R&D at AstraZeneca, echoed this sentiment, stating that the DeLLphi-305 outcomes are poised to "redefine treatment standards" for ES-SCLC patients. She further emphasized the results’ reinforcement of Imfinzi’s position as "the backbone immunotherapy in this setting," suggesting a strategic strengthening of AstraZeneca’s oncology portfolio.
n
William Blair analysts further highlighted the "significant market opportunity for Imdelltra," recognizing its potential to capture a substantial share in a market desperate for more effective therapies. For context, GlobalData analysis benchmarks the success of such therapies against combinations like Roche’s Tecentriq (atezolizumab) and Jazz Pharmaceuticals’ Zepzelca (lurbinectedin), which received FDA approval in October 2025 following positive data from the Phase III IMforte trial. The data from DeLLphi-305, however, suggests a new benchmark may have been set, promising a brighter future for patients battling this aggressive disease.
n
Roche’s Divarasib Outshines First-Generation KRAS Inhibitors in NSCLC
n
Another standout presentation at ESMO 2026 centered on Roche’s highly selective KRAS G12C inhibitor, divarasib. The Swiss pharmaceutical powerhouse presented compelling data from the Phase III Krascendo I trial (NCT06497556), which rigorously evaluated divarasib’s safety and efficacy against currently approved first-generation KRAS G12C inhibitors, specifically Amgen’s Lumakras (sotorasib) and Bristol Myers Squibb’s (BMS) Krazati (adagrasib). The study focused on patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had previously undergone one to three lines of systemic therapy.
n
KRAS G12C mutations represent a significant oncogenic driver in NSCLC, historically considered "undruggable" until the advent of first-generation inhibitors. While these initial therapies offered a glimmer of hope, their efficacy and toxicity profiles left room for improvement, spurring the development of next-generation agents like divarasib.
n
Chronology of Superiority: Krascendo I Demonstrates Enhanced Efficacy and Tolerability
n
During another Presidential Symposium, Roche unveiled results demonstrating divarasib’s clear superiority over its predecessors. The trial showed that divarasib significantly bolstered median PFS to 9.8 months, a marked improvement compared to the average of 5.7 months observed in the comparator treatment arms at a median follow-up of 14.3 months. More impressively, divarasib offered a significant 5.7-month improvement in OS, with patients receiving Roche’s therapy achieving a median OS of 17.7 months, contrasting sharply with the average of 12 months for the control therapies.
n
Beyond efficacy, divarasib also presented a more favorable safety profile. A lower proportion of patients in the divarasib arm experienced Grade 3 and 4 treatment-emergent adverse events (TEAEs) – 24.6% compared to 34.5% in the control arm. Notably, hepatotoxicity, a concern with some first-generation inhibitors, was also lower in the divarasib arm. Professor Benjamin Besse of the Institut Gustave Roussy highlighted this aspect, noting that divarasib could be "more immunotherapy (IO) friendly than sotorasib," which has sometimes been associated with liver toxicity following IO treatment. This suggests better compatibility for combination strategies.
n
Official Responses and Future Implications
n
Professor Besse’s comments underscored the significance of these findings: "Results from Krascendo 1 trial indicate that the higher potency of divarasib could translate into a new standard of care." He further emphasized that future leaders in this therapeutic space would likely distinguish themselves not just by efficacy but also by "differentiated toxicity." This holistic view of patient benefit – combining superior efficacy with improved tolerability – positions divarasib as a potential game-changer.
n
Building on this second-line success, Roche is now strategically advancing divarasib into the frontline setting. The Krascendo 2 trial (NCT06793215) is already underway, evaluating divarasib in combination with MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) versus Keytruda plus chemotherapy in the KRAS G12C mutant NSCLC population. This aggressive development strategy reflects the immense promise seen in divarasib.
n
The broader landscape of RAS pathway inhibitors is currently garnering significant attention from both industry and physicians, hailed for their potential to tackle cancers traditionally linked to poor outcomes. This excitement was recently amplified by the landmark pancreatic cancer approval of Revolution Medicines’ pan-RAS(ON) inhibitor, Rasonque (daraxonrasib). Rasonque, which is also in development for RAS-mutant NSCLC, "shook up the field" by almost doubling OS in the pancreatic cancer setting, signaling a new era for RAS-targeted therapies and setting a high bar for other drugs in this class.
n
MSD’s Sac-TMT Plus Keytruda Redefines First-Line Therapy for PD-L1-Negative NSCLC
n
The burgeoning antibody-drug conjugate (ADC) modality firmly held the spotlight at ESMO 2026, and among the most compelling presentations was new data from the Phase III OptiTROP-Lung06 study (NCT06711900). This pivotal trial explored the potential of sacituzumab tirumotecan (sac-TMT), a TROP2-targeted ADC developed by MSD and Kelun-Biotech, in combination with Keytruda, against the current standard of care (Keytruda plus platinum-based chemotherapy) in frontline, PD-L1-negative, metastatic non-squamous NSCLC.
n
PD-L1-negative NSCLC represents a particularly challenging subset of lung cancer, as these patients typically derive less benefit from single-agent immunotherapy. The search for more effective and tolerable first-line regimens has been a priority, and the TROP2 ADC platform, known for its ability to deliver cytotoxic agents directly to cancer cells expressing the TROP2 protein, offers a promising avenue.
n
Chronology of a New Standard: OptiTROP-Lung06’s Impact
n
During an oral presentation at the event, MSD and Kelun-Biotech revealed that the sac-TMT-Keytruda combination significantly prolonged PFS. The risk of disease progression or death dropped by an impressive 51% in the investigational arm. While overall survival data had not yet matured at the interim analysis, the observed trend strongly supported the investigational arm, indicating a potential long-term benefit for patients.
n
Beyond extending PFS, patients receiving sac-TMT and Keytruda also exhibited more durable responses to treatment. The median duration of response (DoR) for this targeted combination was 13.6 months, significantly longer than the 6.8 months achieved with Keytruda and chemotherapy.
n
Furthermore, the ADC-IO combination appeared to be more tolerable than the chemotherapy-containing regimen. Researchers observed fewer Grade 3 or higher TEAEs in the sac-TMT-Keytruda group, as well as fewer TEAEs that led to dose reduction or permanent treatment discontinuation. This improved tolerability profile is critical for maintaining patient quality of life and adherence to treatment, particularly in the frontline setting.
n
Official Responses and Broader Implications
n
Dr. Caicun Zhou, Director of Oncology at Shanghai East Hospital, Tongji University, underscored the importance of these findings, stating that the results "further highlight the clinical benefits of sac-TMT alongside Keytruda in first-line PD-L1-negative EGFR/ALK-negative advanced non-squamous NSCLC." He also connected these results to prior data: "Together with the OptiTROP-Lung05 results previously presented at 2026 ASCO, this combination regimen has shown PFS benefit in patients with NSCLC without actionable genomic alterations, regardless of PD-L1 expression, providing new Phase III evidence as first-line treatment." This comprehensive efficacy across PD-L1 expression levels positions sac-TMT as a versatile and potent therapeutic option.
MSD and Kelun are actively evaluating sac-TMT’s potential across a wide spectrum of solid tumor indications, including gynecologic cancers (endometrial and ovarian), various forms of breast, lung, gastrointestinal, and genitourinary cancers. Analysts at GlobalData, the parent company of Clinical Trials Arena, have high expectations for sac-TMT, predicting it will achieve blockbuster status by 2030, with sales projected to exceed $3.6 billion by the end of the forecast period in 2032. This financial outlook underscores the drug’s significant market potential and the anticipated impact it will have on patient care.
BioNTech’s Pumitamig Shows Encouraging Potential in Advanced NSCLC
The bispecific antibody modality also captured significant attention at ESMO 2026, with numerous drugs targeting validated pathways like PD-L1 and VEGF-A progressing through clinical pipelines. Among these, BioNTech’s PD-L1 x VEGF-A-targeting candidate, pumitamig, presented compelling early data, offering a new hope for patients with advanced NSCLC who have exhausted prior lines of therapy.
Many patients with metastatic NSCLC eventually progress after initial immunotherapy and chemotherapy regimens, leaving them with limited treatment options and a dire prognosis. Bispecific antibodies, by simultaneously targeting two distinct pathways, offer the potential for enhanced anti-tumor activity and circumventing resistance mechanisms.
Chronology of Emerging Promise: ROSETTA-Lung107’s Initial Readout
At ESMO, the German biopharmaceutical company presented the first data from the Phase II ROSETTA-Lung107 trial (NCT06841055). This study is investigating pumitamig’s potential in combination with docetaxel in patients with metastatic NSCLC who have progressed after both immunotherapy and chemotherapy – a particularly challenging, heavily pre-treated population.
Early results from BioNTech indicate that pumitamig has displayed "encouraging responses" across various histologies, including both squamous and non-squamous NSCLC, and notably, across all levels of PD-L1 expression. In the 30 efficacy-evaluable patients, the confirmed objective response rate (ORR) was an encouraging 36.7%.
In terms of disease control, the median PFS observed in this study was 6.9 months. This represents a significant improvement over the typical standard-of-care (SOC) docetaxel, which generally delivers a median PFS of around 3.6-3.9 months for non-squamous and squamous metastatic NSCLC, respectively, after prior exposure to IO and chemotherapy. The near doubling of PFS is a substantial achievement in this difficult-to-treat patient group.
Official Responses and Future Validation
Jefferies analysts, reviewing the ROSETTA-Lung107 results, commented that the efficacy "looks broadly consistent with ivonescimab." Akeso and Summit Therapeutics’ ivonescimab, another PD-L1 x VEGF bispecific antibody, is currently under review by US regulators for the treatment of a specific type of NSCLC, suggesting a similar therapeutic niche and competitive landscape.
The analysts further noted, "Activity was seen across PD-L1 expression levels, though we’ll caveat the small sample size, and safety looks broadly consistent with prior ivonescimab experience." While acknowledging the preliminary nature of Phase II data and the small sample size, their overall assessment was positive: "Overall, we think the early data is encouraging, though randomised validation is still needed." This highlights the need for larger, controlled trials to confirm these promising early signals and establish pumitamig’s definitive role in the treatment algorithm. The ongoing development of pumitamig underscores the continued innovation in bispecific antibody design and their growing importance in oncology.
Overarching Implications and the Future of Lung Cancer Care
The 2026 ESMO Congress has unequivocally demonstrated that the fight against lung cancer is entering a new, dynamic phase. The breakthroughs presented in Madrid collectively paint a picture of an evolving treatment landscape, characterized by increasingly sophisticated and effective therapeutic strategies.
The success of Amgen and AstraZeneca’s Imdelltra-Imfinzi combination in ES-SCLC offers a beacon of hope for a patient population with historically limited options, promising to significantly extend both survival and disease control. Roche’s divarasib, by demonstrating superior efficacy and improved tolerability over first-generation KRAS G12C inhibitors, sets a new benchmark for targeted therapy in NSCLC and paves the way for frontline combinations. The impressive data from MSD and Kelun-Biotech’s sac-TMT with Keytruda heralds a new era for ADCs in the first-line treatment of PD-L1-negative NSCLC, offering a more effective and better-tolerated alternative to chemotherapy. Finally, BioNTech’s pumitamig, though in earlier stages, offers encouraging prospects for advanced NSCLC patients who have exhausted other treatments, highlighting the growing utility of bispecific antibodies.
These advancements are not merely incremental; they represent a concerted effort to address the diverse genetic and clinical complexities of lung cancer. The emphasis on combination therapies, next-generation targeted agents, and innovative modalities like ADCs and bispecific antibodies reflects a deeper understanding of tumor biology and a commitment to precision medicine.
As the echoes of ESMO 2026 fade from Madrid, the implications for patients and clinicians resonate globally. These findings will undoubtedly influence clinical practice guidelines, stimulate further research, and ultimately lead to new regulatory approvals. The journey to conquer lung cancer is far from over, but the revelations from this year’s congress have provided invaluable momentum, fostering a renewed sense of optimism that a future with improved outcomes and enhanced quality of life for lung cancer patients is not just a hope, but an increasingly tangible reality.
